Study Looks at Safety of CGRP’s in Relation to People With Raynaud Phenomenon from JAMA Network

“A New Generation of Headache Drugs” from Nature

Monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor are already having a big impact on migraine. But they have the potential to do so much more. Peter Goadsby sat in the audience, intrigued. The Australian medical student had come to...
Subscribe To Our Weekly Newsletter

Subscribe To Our Weekly Newsletter

Get a weekly digest of our posts straight to your inbox! We promise, no spam ever.

You have Successfully Subscribed!

Pin It on Pinterest